Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 318

1.

Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients.

Frerichs KA, Bosman PWC, van Velzen JF, Fraaij PLA, Koopmans MPG, Rimmelzwaan GF, Nijhof IS, Bloem AC, Mutis T, Zweegman S, van de Donk NWCJ.

Haematologica. 2019 Sep 26. pii: haematol.2019.231860. doi: 10.3324/haematol.2019.231860. [Epub ahead of print]

2.

Influenza virus-specific CD4+ and CD8+ T cell-mediated immunity induced by infection and vaccination.

Jansen JM, Gerlach T, Elbahesh H, Rimmelzwaan GF, Saletti G.

J Clin Virol. 2019 Oct;119:44-52. doi: 10.1016/j.jcv.2019.08.009. Epub 2019 Aug 24. Review.

PMID:
31491709
3.

Response Modifiers: Tweaking the Immune Response Against Influenza A Virus.

Elbahesh H, Gerlach T, Saletti G, Rimmelzwaan GF.

Front Immunol. 2019 Apr 12;10:809. doi: 10.3389/fimmu.2019.00809. eCollection 2019. Review.

4.

Epistatic interactions can moderate the antigenic effect of substitutions in haemagglutinin of influenza H3N2 virus.

Koel BF, Burke DF, van der Vliet S, Bestebroer TM, Rimmelzwaan GF, Osterhaus ADME, Smith DJ, Fouchier RAM.

J Gen Virol. 2019 May;100(5):773-777. doi: 10.1099/jgv.0.001263. Epub 2019 Apr 24.

PMID:
31017567
5.

Diet May Drive Influenza A Virus Exposure in African Mammals.

Soilemetzidou ES, De Bruin E, Franz M, Aschenborn OHK, Rimmelzwaan GF, Van Beek R, Koopmans M, Greenwood AD, Czirják GÁ.

J Infect Dis. 2019 Mar 6. pii: jiz032. doi: 10.1093/infdis/jiz032. [Epub ahead of print]

PMID:
30838397
6.

Divergent SATB1 expression across human life span and tissue compartments.

Nüssing S, Koay HF, Sant S, Loudovaris T, Mannering SI, Lappas M, D Udekem Y, Konstantinov IE, Berzins SP, Rimmelzwaan GF, Turner SJ, Clemens EB, Godfrey DI, Nguyen TH, Kedzierska K.

Immunol Cell Biol. 2019 May;97(5):498-511. doi: 10.1111/imcb.12233. Epub 2019 Feb 25.

7.

Influenza Virus Infections and Cellular Kinases.

Meineke R, Rimmelzwaan GF, Elbahesh H.

Viruses. 2019 Feb 20;11(2). pii: E171. doi: 10.3390/v11020171. Review.

8.

Recombinant influenza A viruses as vaccine vectors.

Gerlach T, Elbahesh H, Saletti G, Rimmelzwaan GF.

Expert Rev Vaccines. 2019 Apr;18(4):379-392. doi: 10.1080/14760584.2019.1582338. Epub 2019 Mar 4.

PMID:
30777467
9.

A prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis.

Strijbos E, Tannemaat MR, Alleman I, de Meel RHP, Bakker JA, van Beek R, Kroon FP, Rimmelzwaan GF, Verschuuren JJGM.

Vaccine. 2019 Feb 8;37(7):919-925. doi: 10.1016/j.vaccine.2019.01.007. Epub 2019 Jan 16.

PMID:
30660402
10.

Broadly protective influenza vaccines: design and production platforms.

Elbahesh H, Saletti G, Gerlach T, Rimmelzwaan GF.

Curr Opin Virol. 2019 Feb;34:1-9. doi: 10.1016/j.coviro.2018.11.005. Epub 2018 Nov 27. Review.

PMID:
30497050
11.

Induction of Cross-Clade Antibody and T-Cell Responses by a Modified Vaccinia Virus Ankara-Based Influenza A(H5N1) Vaccine in a Randomized Phase 1/2a Clinical Trial.

de Vries RD, Altenburg AF, Nieuwkoop NJ, de Bruin E, van Trierum SE, Pronk MR, Lamers MM, Richard M, Nieuwenhuijse DF, Koopmans MPG, Kreijtz JHCM, Fouchier RAM, Osterhaus ADME, Sutter G, Rimmelzwaan GF.

J Infect Dis. 2018 Jul 13;218(4):614-623. doi: 10.1093/infdis/jiy214.

12.

T cells and ILC2s are major effector cells in influenza-induced exacerbation of allergic airway inflammation in mice.

Li BWS, de Bruijn MJW, Lukkes M, van Nimwegen M, Bergen IM, KleinJan A, GeurtsvanKessel CH, Andeweg A, Rimmelzwaan GF, Hendriks RW.

Eur J Immunol. 2019 Jan;49(1):144-156. doi: 10.1002/eji.201747421. Epub 2018 Jun 11.

13.

Influenza vaccines: 'tailor-made' or 'one fits all'.

Saletti G, Gerlach T, Rimmelzwaan GF.

Curr Opin Immunol. 2018 Aug;53:102-110. doi: 10.1016/j.coi.2018.04.015. Epub 2018 May 4. Review.

PMID:
29734023
14.

Effects of pre-existing orthopoxvirus-specific immunity on the performance of Modified Vaccinia virus Ankara-based influenza vaccines.

Altenburg AF, van Trierum SE, de Bruin E, de Meulder D, van de Sandt CE, van der Klis FRM, Fouchier RAM, Koopmans MPG, Rimmelzwaan GF, de Vries RD.

Sci Rep. 2018 Apr 24;8(1):6474. doi: 10.1038/s41598-018-24820-2.

15.

H1N1pdm09 Influenza Virus and Its Descendants Lack Extra-epitopic Amino Acid Residues Associated With Reduced Recognition by M158-66-Specific CD8+ T Cells.

van de Sandt CE, Sagong KA, Pronk MR, Bestebroer TM, Spronken MI, Koopmans MPG, Fouchier RAM, Rimmelzwaan GF.

J Infect Dis. 2018 Jul 13;218(4):581-585. doi: 10.1093/infdis/jiy218.

16.

Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice.

Magnusson SE, Altenburg AF, Bengtsson KL, Bosman F, de Vries RD, Rimmelzwaan GF, Stertman L.

Immunol Res. 2018 Apr;66(2):224-233. doi: 10.1007/s12026-018-8991-x.

17.

Variation at Extra-epitopic Amino Acid Residues Influences Suppression of Influenza Virus Replication by M158-66 Epitope-Specific CD8+ T Lymphocytes.

van de Sandt CE, Pronk MR, van Baalen CA, Fouchier RAM, Rimmelzwaan GF.

J Virol. 2018 May 14;92(11). pii: e00232-18. doi: 10.1128/JVI.00232-18. Print 2018 Jun 1.

18.

Development of Endotoxin Tolerance Does Not Influence the Response to a Challenge with the Mucosal Live-Attenuated Influenza Vaccine in Humans In Vivo.

Koch RM, Kox M, Thijs EJM, Rahamat-Langendoen JC, van de Veerdonk FL, Gerretsen J, Schloesser J, Diavatopoulos D, Rimmelzwaan GF, Netea MG, van der Hoeven JG, de Jonge MI, Pickkers P.

Front Immunol. 2017 Dec 11;8:1600. doi: 10.3389/fimmu.2017.01600. eCollection 2017.

19.

Primary Human Influenza B Virus Infection Induces Cross-Lineage Hemagglutinin Stalk-Specific Antibodies Mediating Antibody-Dependent Cellular Cytoxicity.

de Vries RD, Nieuwkoop NJ, van der Klis FRM, Koopmans MPG, Krammer F, Rimmelzwaan GF.

J Infect Dis. 2017 Dec 27;217(1):3-11. doi: 10.1093/infdis/jix546.

20.

Report on eighth WHO meeting on development of influenza vaccines that induce broadly protective and long-lasting immune responses: Chicago, USA, 23-24 August 2016.

Ortiz JR, Hickling J, Jones R, Donabedian A, Engelhardt OG, Katz JM, Madhi SA, Neuzil KM, Rimmelzwaan GF, Southern J, Spiro DJ, Hombach J.

Vaccine. 2018 Feb 8;36(7):932-938. doi: 10.1016/j.vaccine.2017.11.061. Epub 2017 Dec 6.

21.

[Influenza vaccination of patients with solid tumours during chemotherapy: efficacy and safety].

Vollaard AM, Schreuder I, Slok-Raijmakers L, Opstelten W, Rimmelzwaan GF, Gelderblom AJ.

Ned Tijdschr Geneeskd. 2017;161:D2066. Dutch.

PMID:
29027518
22.

Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo.

Altenburg AF, van de Sandt CE, Li BWS, MacLoughlin RJ, Fouchier RAM, van Amerongen G, Volz A, Hendriks RW, de Swart RL, Sutter G, Rimmelzwaan GF, de Vries RD.

Sci Rep. 2017 Aug 17;7(1):8580. doi: 10.1038/s41598-017-08719-y.

23.

Protein and modified vaccinia virus Ankara-based influenza virus nucleoprotein vaccines are differentially immunogenic in BALB/c mice.

Altenburg AF, Magnusson SE, Bosman F, Stertman L, de Vries RD, Rimmelzwaan GF.

Clin Exp Immunol. 2017 Oct;190(1):19-28. doi: 10.1111/cei.13004. Epub 2017 Jul 24.

24.

A compensatory mutagenesis study of a conserved hairpin in the M gene segment of influenza A virus shows its role in virus replication.

Spronken MI, van de Sandt CE, de Jongh EP, Vuong O, van der Vliet S, Bestebroer TM, Olsthoorn RCL, Rimmelzwaan GF, Fouchier RAM, Gultyaev AP.

RNA Biol. 2017 Nov 2;14(11):1606-1616. doi: 10.1080/15476286.2017.1338243. Epub 2017 Jul 21.

25.

Human CD8+ T Cells Damage Noninfected Epithelial Cells during Influenza Virus Infection In Vitro.

van de Sandt CE, Bárcena M, Koster AJ, Kasper J, Kirkpatrick CJ, Scott DP, de Vries RD, Herold S, Rimmelzwaan GF, Kuiken T, Short KR.

Am J Respir Cell Mol Biol. 2017 Nov;57(5):536-546. doi: 10.1165/rcmb.2016-0377OC.

PMID:
28613916
26.

Neuraminidase-mediated haemagglutination of recent human influenza A(H3N2) viruses is determined by arginine 150 flanking the neuraminidase catalytic site.

Mögling R, Richard MJ, Vliet SV, Beek RV, Schrauwen EJA, Spronken MI, Rimmelzwaan GF, Fouchier RAM.

J Gen Virol. 2017 Jun;98(6):1274-1281. doi: 10.1099/jgv.0.000809. Epub 2017 Jun 13.

27.

Editorial overview: Viral immunology: Dealing with bad news.

Yewdell JW, Rimmelzwaan GF.

Curr Opin Virol. 2017 Feb;22:viii-x. doi: 10.1016/j.coviro.2017.02.002. No abstract available.

PMID:
28279326
28.

Distinct and Overlapping Functions of TEC Kinase and BTK in B Cell Receptor Signaling.

de Bruijn MJ, Rip J, van der Ploeg EK, van Greuningen LW, Ta VT, Kil LP, Langerak AW, Rimmelzwaan GF, Ellmeier W, Hendriks RW, Corneth OB.

J Immunol. 2017 Apr 15;198(8):3058-3068. doi: 10.4049/jimmunol.1601285. Epub 2017 Mar 8.

29.

Microarray profile of the humoral immune response to influenza vaccination in breast cancer patients treated with chemotherapy.

Wumkes ML, van der Velden AM, de Bruin E, Meerveld-Eggink A, Koopmans MP, Rimmelzwaan GF, Rijkers GT, Biesma DH.

Vaccine. 2017 Mar 1;35(9):1299-1305. doi: 10.1016/j.vaccine.2017.01.039. Epub 2017 Feb 3.

PMID:
28169075
30.

Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection.

de Vries RD, Nieuwkoop NJ, Pronk M, de Bruin E, Leroux-Roels G, Huijskens EGW, van Binnendijk RS, Krammer F, Koopmans MPG, Rimmelzwaan GF.

Vaccine. 2017 Jan 5;35(2):238-247. doi: 10.1016/j.vaccine.2016.11.082. Epub 2016 Nov 30.

PMID:
27914742
31.

ViroSpot microneutralization assay for antigenic characterization of human influenza viruses.

van Baalen CA, Jeeninga RE, Penders GH, van Gent B, van Beek R, Koopmans MP, Rimmelzwaan GF.

Vaccine. 2017 Jan 3;35(1):46-52. doi: 10.1016/j.vaccine.2016.11.060. Epub 2016 Nov 26.

32.

Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice.

Altenburg AF, van de Sandt CE, van Trierum SE, De Gruyter HLM, van Run PRWA, Fouchier RAM, Roose K, Saelens X, Volz A, Sutter G, de Vries RD, Rimmelzwaan GF.

J Virol. 2016 Oct 28;90(22):10209-10219. doi: 10.1128/JVI.01633-16. Print 2016 Nov 15.

33.

Viral vector-based influenza vaccines.

de Vries RD, Rimmelzwaan GF.

Hum Vaccin Immunother. 2016 Nov;12(11):2881-2901. Epub 2016 Jul 25. Review.

34.

Universal influenza vaccines: a realistic option?

de Vries RD, Altenburg AF, Rimmelzwaan GF.

Clin Microbiol Infect. 2016 Dec 1;22 Suppl 5:S120-S124. doi: 10.1016/j.cmi.2015.12.005. Epub 2016 Apr 26.

35.

Influenza in long-term Dutch travelers in the tropics: symptoms and infections.

Whelan J, Rimmelzwaan GF, van den Hoek A, Belderok SM, Sonder GJB.

BMC Infect Dis. 2016 Apr 16;16:158. doi: 10.1186/s12879-016-1502-6.

36.

Multiple Natural Substitutions in Avian Influenza A Virus PB2 Facilitate Efficient Replication in Human Cells.

Mänz B, de Graaf M, Mögling R, Richard M, Bestebroer TM, Rimmelzwaan GF, Fouchier RAM.

J Virol. 2016 Jun 10;90(13):5928-5938. doi: 10.1128/JVI.00130-16. Print 2016 Jul 1.

37.

Amino Acid Substitutions That Affect Receptor Binding and Stability of the Hemagglutinin of Influenza A/H7N9 Virus.

Schrauwen EJ, Richard M, Burke DF, Rimmelzwaan GF, Herfst S, Fouchier RA.

J Virol. 2016 Jan 20;90(7):3794-9. doi: 10.1128/JVI.03052-15.

38.

Differential Recognition of Influenza A Viruses by M158-66 Epitope-Specific CD8+ T Cells Is Determined by Extraepitopic Amino Acid Residues.

van de Sandt CE, Kreijtz JH, Geelhoed-Mieras MM, Nieuwkoop NJ, Spronken MI, van de Vijver DA, Fouchier RA, Osterhaus AD, Rimmelzwaan GF.

J Virol. 2015 Nov 4;90(2):1009-22. doi: 10.1128/JVI.02439-15. Print 2016 Jan 15.

39.

Report on the second WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Geneva, Switzerland, 5-7 May 2014.

Cox NJ, Hickling J, Jones R, Rimmelzwaan GF, Lambert LC, Boslego J, Rudenko L, Yeolekar L, Robertson JS, Hombach J, Ortiz JR.

Vaccine. 2015 Nov 27;33(48):6503-10. doi: 10.1016/j.vaccine.2015.10.014. Epub 2015 Oct 23.

PMID:
26478203
40.

Host immunity dictates influenza A(H1N1)pdm09 infection outcome in hematology-oncology patients.

Gooskens J, Marijt WA, van Essen EH, Rimmelzwaan GF, Kroes AC.

Bone Marrow Transplant. 2016 Jan;51(1):138-41. doi: 10.1038/bmt.2015.214. Epub 2015 Sep 21. No abstract available.

PMID:
26389836
41.

Influenza B viruses: not to be discounted.

van de Sandt CE, Bodewes R, Rimmelzwaan GF, de Vries RD.

Future Microbiol. 2015;10(9):1447-65. doi: 10.2217/fmb.15.65. Epub 2015 Sep 11. Review.

PMID:
26357957
42.

Developing Universal Influenza Vaccines: Hitting the Nail, Not Just on the Head.

Wiersma LC, Rimmelzwaan GF, de Vries RD.

Vaccines (Basel). 2015 Mar 26;3(2):239-62. doi: 10.3390/vaccines3020239. Review.

43.

Heterosubtypic immunity to H7N9 influenza virus in isogenic guinea pigs after infection with pandemic H1N1 virus.

Wiersma LC, Vogelzang-van Trierum SE, Kreijtz JH, van Amerongen G, van Run P, Ladwig M, Banneke S, Schaefer H, Fouchier RA, Kuiken T, Osterhaus AD, Rimmelzwaan GF.

Vaccine. 2015 Dec 8;33(49):6977-82. doi: 10.1016/j.vaccine.2015.08.038. Epub 2015 Aug 25.

PMID:
26319067
44.

Virus replication kinetics and pathogenesis of infection with H7N9 influenza virus in isogenic guinea pigs upon intratracheal inoculation.

Wiersma LC, Kreijtz JH, Vogelzang-van Trierum SE, van Amerongen G, van Run P, Ladwig M, Banneke S, Schaefer H, Fouchier RA, Kuiken T, Osterhaus AD, Rimmelzwaan GF.

Vaccine. 2015 Dec 8;33(49):6983-7. doi: 10.1016/j.vaccine.2015.08.050. Epub 2015 Aug 22.

PMID:
26307235
45.

Optimisations and Challenges Involved in the Creation of Various Bioluminescent and Fluorescent Influenza A Virus Strains for In Vitro and In Vivo Applications.

Spronken MI, Short KR, Herfst S, Bestebroer TM, Vaes VP, van der Hoeven B, Koster AJ, Kremers GJ, Scott DP, Gultyaev AP, Sorell EM, de Graaf M, Bárcena M, Rimmelzwaan GF, Fouchier RA.

PLoS One. 2015 Aug 4;10(8):e0133888. doi: 10.1371/journal.pone.0133888. eCollection 2015.

46.

Antigenic Maps of Influenza A(H3N2) Produced With Human Antisera Obtained After Primary Infection.

Fonville JM, Fraaij PL, de Mutsert G, Wilks SH, van Beek R, Fouchier RA, Rimmelzwaan GF.

J Infect Dis. 2016 Jan 1;213(1):31-8. doi: 10.1093/infdis/jiv367. Epub 2015 Jul 3.

47.

Universal influenza vaccines, science fiction or soon reality?

de Vries RD, Altenburg AF, Rimmelzwaan GF.

Expert Rev Vaccines. 2015;14(10):1299-301. doi: 10.1586/14760584.2015.1060860. Epub 2015 Jun 23.

PMID:
26104835
48.

Low Virulence and Lack of Airborne Transmission of the Dutch Highly Pathogenic Avian Influenza Virus H5N8 in Ferrets.

Richard M, Herfst S, van den Brand JM, Lexmond P, Bestebroer TM, Rimmelzwaan GF, Koopmans M, Kuiken T, Fouchier RA.

PLoS One. 2015 Jun 19;10(6):e0129827. doi: 10.1371/journal.pone.0129827. eCollection 2015.

49.

BCG Vaccination Enhances the Immunogenicity of Subsequent Influenza Vaccination in Healthy Volunteers: A Randomized, Placebo-Controlled Pilot Study.

Leentjens J, Kox M, Stokman R, Gerretsen J, Diavatopoulos DA, van Crevel R, Rimmelzwaan GF, Pickkers P, Netea MG.

J Infect Dis. 2015 Dec 15;212(12):1930-8. doi: 10.1093/infdis/jiv332. Epub 2015 Jun 12.

PMID:
26071565
50.

Induction of influenza (H5N8) antibodies by modified vaccinia virus Ankara H5N1 vaccine.

de Vries RD, De Gruyter HL, Bestebroer TM, Pronk M, Fouchier RA, Osterhaus AD, Sutter G, Kreijtz JH, Rimmelzwaan GF.

Emerg Infect Dis. 2015 Jun;21(6):1086-8. doi: 10.3201/eid2106.150021. No abstract available.

Supplemental Content

Loading ...
Support Center